Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor

Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation of this pathway may be a mechanism of acquired resistance. Therefore, MEK inhibition with trametinib and...

Full description

Saved in:
Bibliographic Details
Published in:JCO Precis Oncol
Main Authors: Luo, Jia, Makhnin, Alex, Tobi, Yosef, Ahn, Linda, Hayes, Sara A., Iqbal, Afsheen, Ng, Kenneth, Arcila, Maria E., Riely, Gregory J., Kris, Mark G., Yu, Helena A.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2021
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8232136/
https://ncbi.nlm.nih.gov/pubmed/34250388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00315
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items